Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06815432 · ClinicalTrials.gov registry record · Phase 1
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
A Phase 1 study of Glioblastoma Multiforme of Brain, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT06815432 is a Phase 1 study of Glioblastoma Multiforme of Brain that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 27 participants, below the 156-participant average among 11 other Glioblastoma Multiforme of Brain trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06815432, a Phase 1 study of Glioblastoma Multiforme of Brain, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T-cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat participants with cancers. They have shown promise, but have not been strong enough to cure most participants. The study team has found from previous research that we can put a new gene (a tiny part of what makes-up DNA and carries the participants traits) into T cells that will make them recognize cancer cells and kill them. In the lab, the study team has made several genes called a chimeric antigen receptor (CAR), from an antibody called GC33. The antibody GC33 recognizes a protein found on the participants brain tumor. This CAR is called GPC3-CAR. To make this CAR more effective, the study has also added a gene that includes IL15. IL15 is a protein that helps CAR T cells grow better and stay in the blood longer so that they may kill tumors better. The mixture of GPC3-CAR and IL15 killed tumor cells better in the laboratory when compared with CAR T cells that did not have IL15. This study will test T cells with the IL15 GPC3-CAR (GO-CART T cells) in participants with GPC3-positive brain tumors. T cells made to carry a gene called iCasp9 can be killed when they encounter a specific drug called AP1903. The study team will insert the iCasp9 and IL15 together into the T cells using a virus that has been made for this study. The drug (AP1903) is an experimental drug that has been tested in humans with no bad side-effects. The study team will use this drug to kill the T cells if necessary due to side effects. This study will test T cells genetically enginee
Conditions Studied
Interventions
- GENETIC 15.GPC3-CAR T cells
Study Locations (1)
Texas
- Baylor St. Luke's Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-10-10 |
| Est. Completion | 2044-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06815432
The ClinicalTrials.gov registry entry for NCT06815432 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 156-participant average among 11 other Glioblastoma Multiforme of Brain trials with a reported enrollment target (83% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme of Brain appearing as the primary indexed condition, and to 1 intervention - of which 15.GPC3-CAR T cells is the first listed.
NCT06815432 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06815432 about?
NCT06815432 is a clinical study titled "GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma". The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly c...
What is the current status of trial NCT06815432?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2025-10-10. Estimated completion is 2044-12-03.
What conditions does trial NCT06815432 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme of Brain.
What interventions are being tested in trial NCT06815432?
The interventions under investigation include: 15.GPC3-CAR T cells (GENETIC).
Who is sponsoring clinical trial NCT06815432?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06815432 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme of Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®
RECRUITING · Phase 1
-
Trial of C134 in Patients With Recurrent GBM
ACTIVE NOT RECRUITING · Phase 1
-
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
ACTIVE NOT RECRUITING · Phase 1
-
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
RECRUITING
-
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
RECRUITING
-
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.